Ticagrelor

Ticagrelor

• CAS Number: 274693-27-5
• UNSPSC Description: Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
• Target Antigen: P2Y Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Ticagrelor.html
• Purity: 99.98
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO
• Molecular Weight: 522.57
• References & Citations: [1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128(23):2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136(1):234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169(1):82-9.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light, stored under nitrogen)
• Clinical Information: Launched